FDA Approval Sought for Belantamab Mafodotin in Relapsed/Refractory Myeloma

December 17, 2019 – A biologics license application (BLA) has been filed with the FDA for belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, according to GlaxoSmithKline (GSK), the manufacturer of the BCMA-targeting antibody-drug conjugate (ADC). The BLA is based on … (leggi tutto)